Edwards Lifesciences (EW) Hits New 52-Week High Following Analyst Upgrade
Shares of Edwards Lifesciences Corp (NYSE:EW) hit a new 52-week high during trading on Wednesday after UBS Group raised their price target on the stock from $175.00 to $180.00. UBS Group currently has a neutral rating on the stock. Edwards Lifesciences traded as high as $178.69 and last traded at $178.43, with a volume of 748963 shares. The stock had previously closed at $175.44.
A number of other brokerages also recently commented on EW. Citigroup upped their target price on Edwards Lifesciences from $119.00 to $130.00 and gave the stock a “sell” rating in a research note on Monday, February 25th. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target on shares of Edwards Lifesciences in a research report on Sunday, February 3rd. Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research report on Monday, February 4th. Morgan Stanley increased their price target on Edwards Lifesciences from $157.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, December 7th. Finally, Canaccord Genuity increased their price target on Edwards Lifesciences from $177.00 to $186.00 and gave the stock a “positive” rating in a research report on Wednesday, January 16th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $171.10.
In other news, VP Donald E. Bobo, Jr. sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $177.75, for a total value of $977,625.00. Following the transaction, the vice president now owns 24,482 shares in the company, valued at $4,351,675.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Catherine M. Szyman sold 700 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $155.00, for a total value of $108,500.00. Following the completion of the transaction, the vice president now owns 24,482 shares in the company, valued at approximately $3,794,710. The disclosure for this sale can be found here. In the last 90 days, insiders sold 168,522 shares of company stock worth $26,990,579. Company insiders own 1.84% of the company’s stock.
The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.19. The firm has a market cap of $36.45 billion, a P/E ratio of 37.88, a P/E/G ratio of 2.26 and a beta of 0.90.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.17. The company had revenue of $977.70 million during the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a return on equity of 31.09% and a net margin of 19.40%. During the same quarter last year, the firm earned $0.94 earnings per share. As a group, research analysts predict that Edwards Lifesciences Corp will post 5.21 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/edwards-lifesciences-ew-hits-new-52-week-high-following-analyst-upgrade/2890841.html.
About Edwards Lifesciences (NYSE:EW)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: The risks of owning bonds
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.